Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

DDW 2018: Predicting who will get IBD

Written by | 2 Oct 2018

To have a chance of preventing IBD clinicians need to be able to predict who is at risk, based on sensitive and selective risk factors. In a translational… read more.

DDW 2018: Choice in patient management

Written by | 2 Oct 2018

IBD specialists have more treatment options than ever before; yet the optimal use of many agents, old as well as new, remains to be defined. A plenary session… read more.

ASCO 2018: Synchronous primary lung cancers

Written by | 20 Aug 2018

Professor John Lafrate (Harvard Medical School, Boston) and Professor Frank Detterbeck (Yale School of Medicine, New Haven) spoke in a session looking at some of the difficulties with diagnosis and… read more.

ASCO 2018: KEYNOTE-042 shows OS

Written by | 20 Aug 2018

First-line treatment with the PD-1 inhibitor pembrolizumab showed an overall survival benefit compared to platinum-based chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer and… read more.

ASCO 2018: Choices for front-line NSCLC

Written by | 20 Aug 2018

With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…

ASCO 2018: Hot topics in lung cancer

Written by | 20 Aug 2018

Hot topics in lung cancer – interviews from ASCO 2018.

ASCO Highlights

Written by | 20 Aug 2018

June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.

EHA 2018: Molecular profiling in multiple myeloma 

Written by | 3 Aug 2018

In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: The Issue of Frailty in MM

Written by | 24 Jun 2018

When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Access to new agents

Written by | 11 May 2018

Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.